PRQR vs REGN

For growth investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -19. 2% for ProQR Therapeutics N. V. (PRQR). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate ProQR Therapeutics N. V. (PRQR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +17. 4%, compared to -78. 7% for ProQR Therapeutics N. V. (PRQR). Over 10 years, the gap is even starker: REGN returned +68. 0% versus PRQR's -68. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 50β versus ProQR Therapeutics N. V. 's 1. 62β — meaning PRQR is approximately 224% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 28% for ProQR Therapeutics N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.

(REGN) is pulling ahead at 1. 0% versus -19. 2% for ProQR Therapeutics N. V. (PRQR). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -11. 8% for ProQR Therapeutics N. V.. Over a 3-year CAGR, PRQR leads at 62. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -265. 2% for ProQR Therapeutics N. V. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -275. 9% for PRQR. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRQR: 152.

1% to $3. 63.

In this comparison, REGN (0.

6% yield) pays a dividend. PRQR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 50), 0. 6% yield). ProQR Therapeutics N. V. (PRQR) carries a higher beta of 1. 62 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +68. 0%, PRQR: -68. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRQR is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock. REGN pays a dividend while PRQR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.